Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
3M CHG/IPA Prep C · 1 trial · 1 indication
On the abdominal region a responder is a subject with a 2 log10/cm\^2 bacterial reduction at 10 minutes and for whom the skin flora does not return to baseline at the 6-hour sample collection time. On the inguinal region a responder is a subject with a 3 log10/cm\^2 bacterial reduction at 10 minutes and for whom the skin flora does not return to baseline at the 6-hour sample collection time.
10 minute log reduction
| Arm | Type | Description |
|---|---|---|
| 3M CHG/IPA Prep C | EXPERIMENTAL | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
| 3M CHG/IPA Prep CH | EXPERIMENTAL | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
| ChloraPrep | ACTIVE_COMPARATOR | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
| Normal Saline | PLACEBO_COMPARATOR | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
| Name | Type | Description |
|---|---|---|
| 3M CHG/IPA Prep C | DRUG | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
| 3M CHG/IPA Prep CH | DRUG | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
| ChloraPrep | DRUG | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
| Normal Saline | DRUG | Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes. |
Inclusion Criteria: * Subjects of any race * Subjects in good health * Minimum skin flora baseline requirements on abdomen and groin Exclusion Criteria: * Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test area * Topi...
3M CHG/IPA Prep C is an investigational small molecule being studied for bacterial reduction after product application. It is intended to reduce bacteria on the skin in the infectious disease therapeutic area. The drug is currently in Phase 3 clinical development and is not yet approved by the FDA.
3M CHG/IPA Prep C is being developed by 3M Company, a company publicly traded under the ticker symbol MMM. The drug is currently in Phase 3 clinical development for bacterial reduction post-product application.
3M CHG/IPA Prep C is in Phase 3 clinical development. It is an investigational drug being studied for bacterial reduction post-product application. The drug is not yet approved by the FDA and remains in clinical trials.
3M CHG/IPA Prep C has one completed Phase 3 clinical trial, NCT02203591, titled "In Vivo Efficacy Study of Patient Preoperative Preps." The trial enrolled 738 participants in the United States, was randomized and placebo-controlled, and included healthy volunteers aged 18 years and older.
3M CHG/IPA Prep C is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for bacterial reduction post-product application. The drug has completed one clinical trial but has not received regulatory approval.